In vitro activity of caspofungin against strains of Candida;Aktywność in vitro kaspofunginy wobec szczepów z rodzaju Candida

Mikologia Lekarska

Volumn 15, Issue 3, 2008, Pages 135-139

  Wieczorek, Piotr ^a   Sacha, Paweł ^a   Zórawski, Marcin ^a   Jakoniuk, Piotr ^a   Tryniszewska, Elzbieta ^a  

^a Zakład Diagnostyki Mikrobiologicznej AM ^*

Author keywords

Candida; Caspofungin; Susceptibility to antifungals

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; EPSILOMETER TEST; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; MAMMALIA;

EID: 71649111034     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Martin G.S., Mannino D.M., Eaton S., Moss M.: The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med., 2003, 348, 1546-1554.
2. Kołodziej T., Białynicki-Birula R.: Lipidowe i liposomalne formy amfoterycyny B. Mikol. Lek., 2003, 10, 219-221.
3. Białynicki-Birula R., Baran E., Kołodziej T.: Echinokandyny - nowe leki przeciwgrzybicze dostȩpne w praktyce medycznej. Mikol. Lek., 2004, 11, 81-84.
4. Denning D.W.: Echinocandin antifungal drugs. Lancet, 2003, 362, 1142-1151.
5. Paluszewska M.: Worikonazol i kaspofungina - nowe leki przeciwgrzybicze. Współcz. Onkol., 2004, 8, 58-64.
6. DiNubile M.J., Motyl M., Sable C.A.: Caspofungin: the fi rst licensed antifungal drug of the novel echinocandin class. Clin. Microbiol. Newslett., 2004, 26, 81-85.
7. Soustre J., Rodier M.H., Imbert-Bouyer S., Daniault G., Imbert Ch.: Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins. J. Antimicrob. Chemother., 2004, 53, 522-525.
8. Bachmann S.P., VandeWalle K., Ramage G., Patterson T.F., Wickes B.L., Graybill J.R., López-Ribot J.L.: In vitro activity of caspofungin against Candida albicans biofi lms. Antimicrob. Agents Chemother., 2002, 46, 3591-3596.
9. Arathoon E.G.: Clinical effi cacy of echinocandin antifungals. Curr. Opin. Infect. Dis., 2001, 14, 685-691.
10. Cornely O.A., Schmitz K., Aisenbrey S.: The fi rst echinocandin: caspofungin. Mycoses, 2002, 45, 56-60.
11. Keady S., Thacker M.: Caspofungin in the treatment of invasive fungal infections. Intensive Crit. Care Nurs., 2006, 22, 59-62.
12. NCCLS: Reference method for broth dilution antifungal susceptibility testing for Yeats, approved standard document M27-A. National Committee for Clinical Laboratory Standards, 1997, 17, 1-19.
13. Cuenca-Estrella M., Rodriguez D., Almirante B., Morgan J., Planes A.M., Almela M., Mensa J., Sanchez F., Ayats J., Gimenez M., Salvado M., Warnock D.W., Pahissa A., Rodriguez- Tudela J.L.: In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother., 2005, 55, 194-199.
14. Steinbach W.J., Perfect J.R.: Newer antifungal therapy for emerging fungal pathogens. Int. J. Infect. Dis., 2003, 7, 5-20.
15. Letscher-Bru V., Herbrecht R.: Caspofungin: the fi rst representative of a new antifungal class. J. Antimicrob. Chemother., 2003, 51, 513-521.
16. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., Diekema D.J.: Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol., 2004, 42, 3117-3119.
17. Pfaller M.A., Diekema D.J., Messer S.A., Hollis R.J., Jones R.N.: In vitro activities of caspofungin compared with those of fl uconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fl uconazole-resistant isolates. Antimicrob. Agents Chemother., 2003, 47, 1068-1071.
18. Pfaller M.A., Messer S.A., Mills K., Bolmström A., Jones R.N.: Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol., 2001, 39, 4387-4389.
19. Barizal K., Gill C.J., Abruzzo G.K., Flattery A.M., Kong L., Scott P.M., Smith J.G., Leighton C.E., Bouffard A., Dropinski J.F., Balkovec J.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother., 1997, 41, 2326-2332.
20. Kartsonis N., Killar J., Mixson L., Hoe Ch-M., Sable C., Bartizal K., Motyl M.: Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother., 2005, 49, 3616-3623.
21. Baixench M.-T., Aoun N., Desnos-Ollivier M., Garcia-Hermoso D., Bretagne S., Ramires S., Piketty Ch., Dannaoui E.: Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother., 2007, 59, 1076-1083.
22. Balashov S.V., Park S., Perlin D.S.: Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profi ling mutations in FKS1. Antimicrob. Agents Chemother., 2006, 50, 2058-2063.
23. Kartsonis N.A., Nielsen J., Douglas C.M.: Caspofungin: the fi rst in a new class of antifungal agents. Drug Resist. Updates, 2003, 6, 197-218.
24. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., Lee J.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother., 2003, 47, 3149-3154.
25. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., Lupinacci R., Sable C., Kartsonis N., Perfect J., Caspofungin Invasive Candidiasis Study Group: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med., 2002, 347, 2020-2029.
26. Zaoutis T.E., Benjamin D.K., Steinbach W.J.: Antifungal treatment in pediatric patients. Drug Resist. Updates, 2005, 8, 235-245.
27. Puius Y.A., Scully B.: Treatment of Candida albicans pericarditis in a heart trans plant patient. Transpl. Infect. Dis., 2007, 9, 229-232.
28. Pancham S., Hemmaway C., New H., Albert E., Dokal I., Roberts I.A.G., McCloy M.: Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation. Pediatr. Transplantation, 2005, 9, 254-257.
29. Castagnola E., Machetti M., Cappelli B., Molinari A.C., Morreale G., Dodero P., Toma P., Faraci M.: Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refraktory fungal pneumonia in children with acute leukemia or undergoing allogeneic bone marrow transplant. Clin. Microbiol. Infect., 2004, 10, 255-257.
30. Rybowicz J., Gurk-Turner Ch.: Caspofungin: the first agent available in the echinocandin class of antifungals. BUMC Proceedings, 2002, 15, 97-99.